NucleoSpin 96 cfDNA

• Reliable performance and excellent yields from plasma sample material
• Variable sample number in multiples of 8 (8–96 samples)
• Fast processing of 96 samples (1 mL) volume within 104 min and 48 samples (2 mL) within 100 min

NucleoSpin 96 cfDNA automated use with the epMotion 5075

MACHEREY-NAGEL and Eppendorf deliver a sophisticated solution for your high throughput DNA extraction from plasma and serum samples. We adapted the NucleoSpin 96 cfDNA kit on the epMotion 5075vt to speed up your nucleic acid purification workflow. Click here to read our application note NucleoSpin 96 cfDNA on epMotion 5075.

Consistent cfDNA recovery

The isolation of cfDNA from 1 mL human EDTA plasma using the NucleoSpin 96 cfDNA kit on the epMotion 5075vt shows the characteristic peak at approx. 170 bp after measurement by capillary gel electrophoresis using the Agilent Bioanalyzer 2100 system with the High Sensitivity DNA kit.

Comparison of automated and manual processing of 1 mL plasma sample

DNA was isolated from human plasma (n = 8; 1 mL each) using the NucleoSpin® 96 cfDNA kit automated on the epMotion 5075vt platform or via manual purification using the NucleoVac 96 vacuum manifold (MN). The final cfDNA recovery was determined by quantitative real time PCR, using the Quantifiler Human DNA Quantification kit. The TaqMan probe for detecting the target region (human telomerase reverse transcriptase gene) of interest is labeled with a FAM reporter dye (blue bars). VIC dye was used for detecting the amplified Internal PCR control DNA (orange squares), enabling verification that the polymerase, the assay, and the detection instrumentation are working correctly.

Reliable purification of cfDNA from plasma

Human cfDNA was isolated from plasma samples (n = 10) using the NucleoSpin 96 cfDNA kit on the epMotion 5075vt. The total yield was determined using the Agilent Bioanalyzer 2100 system.

Selected citations

1. Stroun et al., 2001 “About the possible origin and mechanism of circulating DNA apoptosis and active DNA release”. Clinica Chimica Acta 

2. Crowley et al., 2013 “Liquid biopsy: monitoring cancer-genetics in the blood” Nature Reviews Clinical Oncology 3. Alix-Panabières and Pantel 2016 “Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy” Cancer Discovery